Document is current
Any future updates will be listed below
-
Authors
Quisenaerts, Tom https://orcid.org/0000-0003-4629-7164
Van Der Auwera, Ilse
Poortmans, Philip https://orcid.org/0000-0001-7400-2293
Reynders, Dries https://orcid.org/0000-0001-6875-048X
Van Dieren, Loïc https://orcid.org/0000-0003-0781-4691
Thiessen, Filip https://orcid.org/0000-0002-4958-3150
Amajoud, Zainab https://orcid.org/0009-0007-5638-8066
Tondu, Thierry https://orcid.org/0000-0002-0996-5170
Punie, Kevin https://orcid.org/0000-0002-1162-7963
Tjalma, Wiebren https://orcid.org/0000-0002-6618-045X
Van Berckelaer, Christophe https://orcid.org/0000-0003-4082-9799
Kindts, Isabelle https://orcid.org/0009-0005-5771-4252
Remouchamps, Vincent https://orcid.org/0000-0003-1188-1977
Depypere, Bernard https://orcid.org/0000-0002-4568-2717
Machiels, Melanie https://orcid.org/0009-0009-9613-4903
-
Funding
Funding for this research was provided by:
Kom op tegen Kanker
- License Information
-
More Information
Article History
Received: 2 March 2026
Accepted: 20 April 2026
First Online: 27 April 2026
Declarations
:
: This study was first approved on 04-JUN-2024 by its central ethical commission, “Commissie Medische Ethiek voor ZAS Vincentius, ZAS Augustinus, ZAS Sint-Jozef en ZAS Hof ter Schelde”, Oosterveldlaan 22, 2610 Wilrijk, Belgium (gza.ec@zas.be). They have also approved the current amendment of the study protocol v4.0, dated 24-DEC-2025, on which this manuscript is based. ZAS vzw is the study sponsor (cancertrials@zas.be).Written informed consent to participate will be obtained from all participants prior to inclusion, after discussing the ICF in detail, and giving the potential participant adequate time to ask questions, reflect and discuss their decision with third parties if they desire
: Not applicable (no individual personal data included).
: The authors declare no competing interests.
